Maze Therapeutics, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Maze Therapeutics appointed Paula Johnson, M.D. (30+ years clinical/research experience, Wellesley College President, J&J board member) and Sophie Kornowski, Pharm.D. (35+ years biopharma leadership, former Boston Pharmaceuticals CEO, ex-Roche executive) to its Board of Directors on August 13, 2026. No financial consideration, equity grants, or compensation details disclosed. The appointments coincide with management's stated focus on advancing MZE829 and MZE782 toward late-stage development and pre-commercial planning.
Why this rating
Board appointments are routine governance events. No material transaction, capital raise, or operational change disclosed. Candidates have relevant biopharma pedigree but announcement contains no equity grants, compensation, or dollar figures. Neutral for stock near-term.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.